{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T04:53:20Z","timestamp":1794113600353,"version":"4.8.0"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"8","license":[{"start":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T00:00:00Z","timestamp":1602547200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Administration of pediatric-inspired chemotherapy to adults up to age 60 with acute lymphoblastic leukemia (ALL) is challenging in part due to toxicities of asparaginase as well as myelosuppression. We conducted a multicenter phase II clinical trial (NCT01920737) investigating a pediatric-inspired regimen, based on the augmented arm of the Children\u2019s Cancer Group 1882 protocol, incorporating 6 doses of pegaspargase 2000 IU\/m2, rationally synchronized to avoid overlapping toxicity with other agents. We treated 39 adults ages 20-60 years (median, 38 years) with newly-diagnosed ALL (n=31) or lymphoblastic lymphoma (n=8). Grade 3-4 hyperbilirubinemia occurred frequently and at higher rates in patients 40-60 (n=18) vs 18-39 (n=21) years (44 vs 10%, p=0.025). However, 8\/9 patients re-challenged with pegaspargase did not experience recurrent grade 3-4 hyperbilirubinemia. Grade 3-4 hypertriglyceridemia and hypofibrinogenemia were common (each 59%). Asparaginase activity at 7-days post-infusion reflected levels associated with adequate asparagine depletion, even among those with antibodies to pegaspargase. Complete response (CR)\/CR with incomplete hematologic recovery was observed post-induction in 38\/39 (97%) patients. Among patients with ALL, rates of MRD negativity by multiparameter flow cytometry were 33% and 83% following Induction Phase I and Phase II, respectively. Event-free and overall survival at 3 years (67.8 and 76.4%) compare favorably to outcomes observed in other series. These results demonstrate pegaspargase can be administered in the context of intensive multi-agent chemotherapy to adults age \u226460 with manageable toxicity. This regimen may serve as an effective backbone into which novel agents may be incorporated in future frontline studies.<\/jats:p>","DOI":"10.3324\/haematol.2020.251686","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T08:39:12Z","timestamp":1602578352000},"page":"2086-2094","source":"Crossref","is-referenced-by-count":44,"title":["Pediatric-inspired chemotherapy incorporating pegaspargase is safe and results in high rates of minimal residual disease negativity in adults up to age 60 with Philadelphia chromosome-negative acute lymphoblastic leukemia"],"prefix":"10.3324","volume":"106","author":[{"given":"Mark B.","family":"Geyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen K.","family":"Ritchie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arati V.","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Vemuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Flynn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meier","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean M.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Roshal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Madhulika","family":"Shukla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Salcedo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Maslak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin S.","family":"Tallman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Douer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,10,13]]},"reference":[{"key":"27798","doi-asserted-by":"crossref","unstructured":"Hunger SP, Mullighan CG. Acute lymphoblastic leukemia in children. N Engl J Med. 2015; 373(16):1541-1552.","DOI":"10.1056\/NEJMra1400972"},{"key":"27799","doi-asserted-by":"crossref","unstructured":"Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980s to the early 21st century. Blood. 2009; 113(7):1408-1411.","DOI":"10.1182\/blood-2008-06-164863"},{"key":"27800","doi-asserted-by":"crossref","unstructured":"Rowe JM, Buck G, Burnett AK. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993. Blood. 2005; 106(12):3760-3767.","DOI":"10.1182\/blood-2005-04-1623"},{"key":"27801","doi-asserted-by":"crossref","unstructured":"Boissel N, Auclerc MF, Lheritier V. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol. 2003; 21(5):774-780.","DOI":"10.1200\/JCO.2003.02.053"},{"key":"27802","doi-asserted-by":"crossref","unstructured":"Stock W, La M, Sanford B. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008; 112(5):1646-1654.","DOI":"10.1182\/blood-2008-01-130237"},{"key":"27803","doi-asserted-by":"crossref","unstructured":"de Bont JM, Holt B, Dekker AW. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia. 2004; 18(12):2032-2035.","DOI":"10.1038\/sj.leu.2403538"},{"key":"27804","doi-asserted-by":"crossref","unstructured":"Douer D, Aldoss I, Lunning MA. Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia. J Clin Oncol. 2014; 32(9):905-911.","DOI":"10.1200\/JCO.2013.50.2708"},{"key":"27805","doi-asserted-by":"crossref","unstructured":"Patel B, Kirkwood AA, Dey A. Pegylated-asparaginase during induction therapy for adult acute lymphoblastic leukaemia: toxicity data from the UKALL14 trial. Leukemia. 2017; 31(1):58-64.","DOI":"10.1038\/leu.2016.219"},{"key":"27806","doi-asserted-by":"crossref","unstructured":"Huguet F, Leguay T, Raffoux E. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL- 2003 study. J Clin Oncol. 2009; 27(6):911-918.","DOI":"10.1200\/JCO.2008.18.6916"},{"key":"27807","doi-asserted-by":"crossref","unstructured":"DeAngelo DJ, Stevenson KE, Dahlberg SE. Long-term outcome of a pediatricinspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015; 29(3):526-534.","DOI":"10.1038\/leu.2014.229"},{"key":"27808","doi-asserted-by":"crossref","unstructured":"Huguet F, Chevret S, Leguay T. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 Clinical Trial. J Clin Oncol. 2018; 36(24):2514-2523.","DOI":"10.1200\/JCO.2017.76.8192"},{"key":"27809","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Beck J, Brandt K. Significant improvement of outcome In adolescents and young adults (AYAs) aged 15-35 Years with acute lymphoblastic leukemia (ALL) with a pediatric derived adult ALL protocol; results Of 1529 AYAs in 2 consecutive trials of The German Multicenter Study Group For Adult ALL (GMALL). Blood. 2013; 122(21):839-839.","DOI":"10.1182\/blood.V122.21.839.839"},{"key":"27810","doi-asserted-by":"crossref","unstructured":"Stock W, Luger SM, Advani AS. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019; 133(14):1548-1559.","DOI":"10.1182\/blood-2018-10-881961"},{"key":"27811","unstructured":"Earl M. Incidence and management of asparaginase-associated adverse events in patients with acute lymphoblastic leukemia. Clin Adv Hematol Oncol. 2009; 7(9):600-606."},{"key":"27812","doi-asserted-by":"crossref","unstructured":"Amylon MD, Shuster J, Pullen J. Intensive high-dose asparaginase consolidation improves survival for pediatric patients with T cell acute lymphoblastic leukemia and advanced stage lymphoblastic lymphoma: a Pediatric Oncology Group study. Leukemia. 1999; 13(3):335-342.","DOI":"10.1038\/sj.leu.2401310"},{"key":"27813","unstructured":"Sallan SE, Hitchcock-Bryan S, Gelber R. Influence of intensive asparaginase in the treatment of childhood non-T-cell acute lymphoblastic leukemia. Cancer Res. 1983; 43(11):5601-5607."},{"key":"27814","doi-asserted-by":"crossref","unstructured":"Stock W, Douer D, DeAngelo DJ. Prevention and management of asparaginase\/ pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma. 2011; 52(12):2237-2253.","DOI":"10.3109\/10428194.2011.596963"},{"key":"27815","doi-asserted-by":"crossref","unstructured":"Asselin BL, Whitin JC, Coppola DJ. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol. 1993; 11(9):1780-1786.","DOI":"10.1200\/JCO.1993.11.9.1780"},{"key":"27816","doi-asserted-by":"crossref","unstructured":"Avramis VI, Sencer S, Periclou AP. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study. Blood. 2002; 99(6):1986-1994.","DOI":"10.1182\/blood.V99.6.1986"},{"key":"27817","doi-asserted-by":"crossref","unstructured":"Muller HJ, Loning L, Horn A. Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL\/NHL-BFM 95 protocols. Br J Haematol. 2000; 110(2):379-384.","DOI":"10.1046\/j.1365-2141.2000.02187.x"},{"key":"27818","doi-asserted-by":"crossref","unstructured":"Larsen EC, Devidas M, Chen S. Dexamethasone and high-dose methotrexate improve outcome for children and young adults with high-risk B-acute lymphoblastic leukemia: a report from Children's Oncology Group Study AALL0232. J Clin Oncol. 2016; 34(20):2380-2388.","DOI":"10.1200\/JCO.2015.62.4544"},{"key":"27819","doi-asserted-by":"crossref","unstructured":"Wetzler M, Sanford BL, Kurtzberg J. Effective asparagine depletion with pegylated asparaginase results in improved outcomes in adult acute lymphoblastic leukemia: Cancer and Leukemia Group B Study 9511. Blood. 2007; 109(10):4164-4167.","DOI":"10.1182\/blood-2006-09-045351"},{"key":"27820","doi-asserted-by":"crossref","unstructured":"Rubenstein JL, Gupta NK, Mannis GN. How I treat CNS lymphomas. Blood. 2013; 122(14):2318-2330.","DOI":"10.1182\/blood-2013-06-453084"},{"key":"27821","doi-asserted-by":"crossref","unstructured":"Khan RB, Shi W, Thaler HT. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?. J Neurooncol. 2002; 58(2):175-178.","DOI":"10.1023\/A:1016077907952"},{"key":"27822","doi-asserted-by":"crossref","unstructured":"Synold TW, Relling MV, Boyett JM. Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia. J Clin Invest. 1994; 94(5):1996-2001.","DOI":"10.1172\/JCI117552"},{"key":"27823","doi-asserted-by":"crossref","unstructured":"Seibel NL, Steinherz PG, Sather HN. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 2008; 111(5):2548-2555.","DOI":"10.1182\/blood-2007-02-070342"},{"key":"27824","doi-asserted-by":"crossref","unstructured":"Nachman JB, Sather HN, Sensel MG. Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy. N Engl J Med. 1998; 338(23):1663-1671.","DOI":"10.1056\/NEJM199806043382304"},{"key":"27825","doi-asserted-by":"crossref","unstructured":"Christ TN, Stock W, Knoebel RW. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen. J Oncol Pharm Pract. 2018; 24(4):299-308.","DOI":"10.1177\/1078155217701291"},{"key":"27826","doi-asserted-by":"crossref","unstructured":"Coustan-Smith E, Mullighan CG, Onciu M. Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol. 2009; 10(2):147-156.","DOI":"10.1016\/S1470-2045(08)70314-0"},{"key":"27827","doi-asserted-by":"crossref","unstructured":"Orvain C, Balsat M, Tavernier E. Thromboembolism prophylaxis in adult patients with acute lymphoblastic leukemia treated in the GRAALL-2005 study. Blood. 2020; 136(3):328-338.","DOI":"10.1182\/blood.2020004919"},{"key":"27828","doi-asserted-by":"crossref","unstructured":"Quist-Paulsen P, Toft N, Heyman M. T-cell acute lymphoblastic leukemia in patients 1-45 years treated with the pediatric NOPHO ALL2008 protocol. Leukemia. 2020; 34(2):347-357.","DOI":"10.1038\/s41375-019-0598-2"},{"key":"27829","doi-asserted-by":"crossref","unstructured":"Luskin MR, DeAngelo DJ. T-cell acute lymphoblastic leukemia: Current approach and future directions. Adv Cell Gene Ther. 2019; 2(4):e70.","DOI":"10.1002\/acg2.70"},{"key":"27830","doi-asserted-by":"crossref","unstructured":"Douer D, Yampolsky H, Cohen LJ. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. Blood. 2007; 109(7):2744-2750.","DOI":"10.1182\/blood-2006-07-035006"},{"key":"27831","doi-asserted-by":"crossref","unstructured":"Lanvers-Kaminsky C, Niemann A, Eveslage M. Asparaginase activities during intensified treatment with pegylated E. coli asparaginase in adults with newly-diagnosed acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(1):138-145.","DOI":"10.1080\/10428194.2019.1658099"},{"key":"27832","doi-asserted-by":"crossref","unstructured":"Patel B, Rai L, Buck G. Minimal residual disease is a significant predictor of treatment failure in non T-lineage adult acute lymphoblastic leukaemia: final results of the international trial UKALL XII\/ECOG2993. Br J Haematol. 2010; 148(1):80-89.","DOI":"10.1111\/j.1365-2141.2009.07941.x"},{"key":"27833","unstructured":"Inotuzumab Ozogamicin and Blinatumomab in treating patients with newly diagnosed recurrent or refractory CD22-positive B-lineage acute lymphoblastic leukemia.Publisher Full Text|"},{"key":"27834","unstructured":"Combination chemotherapy with or without blinatumomab in treating patients with newly diagnosed BCR-ABL-negative B lineage acute lymphoblastic leukemia.Publisher Full Text|"},{"key":"27835","doi-asserted-by":"crossref","unstructured":"Roberts KG, Li Y, Payne-Turner D. Targetable kinase-activating lesions in Phlike acute lymphoblastic leukemia. N Engl J Med. 2014; 371(11):1005-1015.","DOI":"10.1056\/NEJMoa1403088"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.251686\/72469","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2020.251686\/73539","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/10046\/72469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:58:21Z","timestamp":1794045501000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2020.251686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,13]]},"references-count":38,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2021,8,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.251686","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10,13]]}}}